The S&P posted its worst drop in over a month to kick off the new week. And with COVID cases spiking, continued uncertainty in Washington, and a barrage of earnings on tap this week, the traders break down where we’re going from here. Plus there are three stock charts that are starting to signal there’s more danger ahead. What they’re saying and what you should do about it.

Intel shares plunged after the company reported weak results for its data center group. What’s next for the stock that’s been far underperforming the rest of the semi sector. And Gilead gets FDA approval for remdesivir. We break down the rest of the race for a COVID vaccine.